These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1037 related items for PubMed ID: 22843088

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Toxicity after central versus peripheral lung stereotactic body radiation therapy: a propensity score matched-pair analysis.
    Mangona VS, Aneese AM, Marina O, Hymas RV, Ionascu D, Robertson JM, Gallardo LJ, Grills IS.
    Int J Radiat Oncol Biol Phys; 2015 Jan 01; 91(1):124-32. PubMed ID: 25442337
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Lung stereotactic body radiation therapy (SBRT) delivered over 4 or 11 days: a comparison of acute toxicity and quality of life.
    Jain S, Poon I, Soliman H, Keller B, Kim A, Lochray F, Yeung L, Cheung P.
    Radiother Oncol; 2013 Aug 01; 108(2):320-5. PubMed ID: 23993401
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Salvage stereotactic body radiation therapy (SBRT) for local failure after primary lung SBRT.
    Hearn JW, Videtic GM, Djemil T, Stephans KL.
    Int J Radiat Oncol Biol Phys; 2014 Oct 01; 90(2):402-6. PubMed ID: 25017480
    [Abstract] [Full Text] [Related]

  • 8. Incidence and risk factors for chest wall toxicity after risk-adapted stereotactic radiotherapy for early-stage lung cancer.
    Bongers EM, Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S.
    J Thorac Oncol; 2011 Dec 01; 6(12):2052-7. PubMed ID: 22052227
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non-Small-Cell Lung Cancer.
    Park HS, Harder EM, Mancini BR, Decker RH.
    J Thorac Oncol; 2015 May 01; 10(5):832-837. PubMed ID: 25634007
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer: A Retrospective, Single-Center Study of 55 Patients.
    Bhandari RP, Stanford JD, Packianathan S, Duggar WN, Kanakamedala MR, Zhang X, Giri SP, Kumar PP, Harrell LM, Mangana SH, Yang C, Vijayakumar S.
    Oncology; 2016 May 01; 91(4):194-204. PubMed ID: 27427761
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study.
    Feddock J, Arnold SM, Shelton BJ, Sinha P, Conrad G, Chen L, Rinehart J, McGarry RC.
    Int J Radiat Oncol Biol Phys; 2013 Apr 01; 85(5):1325-31. PubMed ID: 23265574
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.